92992-92-2 Usage
Derivative of pyridine
This means that the compound is based on the pyridine molecule, which is a six-membered aromatic heterocyclic compound.
Contains a chlorine atom
The compound has a chlorine atom as one of its substituents.
Contains two amino groups
The compound has two amino groups (-NH2) as substituents.
Used in pharmaceutical research
2-(2-Aminoethylamino)-5-chloropyridine is used as an intermediate in the synthesis of various pharmaceutical drugs.
Known anti-inflammatory agent
The compound has been shown to have anti-inflammatory properties.
Used in production of agrochemicals
The compound is also used in the production of chemicals used in agriculture.
Building block in organic synthesis
The compound can be used as a starting material in the synthesis of other organic compounds.
Versatile compound
The presence of both amino and chlorine groups makes 2-(2-Aminoethylamino)-5-chloropyridine a versatile compound with a wide range of potential applications in the fields of medicine and chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 92992-92-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,9,9 and 2 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 92992-92:
(7*9)+(6*2)+(5*9)+(4*9)+(3*2)+(2*9)+(1*2)=182
182 % 10 = 2
So 92992-92-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H10ClN3/c8-6-1-2-7(11-5-6)10-4-3-9/h1-2,5H,3-4,9H2,(H,10,11)
92992-92-2Relevant articles and documents
Small Molecule Analogs of the Nemo Binding Peptide
-
, (2018/07/04)
The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.
